Breakthrough in Personalized Medicine: 3D Spectral CT-Based Fusion Model Predicts Prognosis and Chemotherapy Benefit in Locally Advanced Rectal Cancer

Strategic Insights -

Research findings on personalized medicine have shed new light on the early identification of high-risk recurrence patients in locally advanced rectal cancer. A study conducted by Koninklijke Philips N.V. - Philips Healthcare revealed that a 3D spectral CT-based fusion model can predict prognosis and postoperative adjuvant chemotherapy benefit in LARCs. The study's findings highlight the importance of quantitative radiological features in personalized risk stratification.

Key Takeaways:

  • The study included 204 LARC patients who underwent SDCT scanning prior to any anticancer treatment, with 2 observers independently measuring iodine concentrations and normalized iodine concentration (NIC) at venous/delayed phases (VP/DP) using two different ROI protocols (2D vs. 3D).
  • The 3D-ROI method achieved satisfactory interobserver accuracy, and multivariate Cox regression analyses indicated that perineural invasion, CD105, histological grade, and NICVP3D values were independent predictors of disease-free survival (DFS).
  • A multidimensional radiological-angiogenesis-clinicopathological integrated model (RACIM) constructed from these predictors achieved area under the receiver operating characteristic (ROC) curve (AUC) values of 0.95 and 0.93 in the training and validation cohorts, respectively.
  • The RACIM-based classifier demonstrated good performance for discriminating patients at high and low risk of recurrence, with patients in the high-risk group showing a favorable response to postoperative adjuvant chemotherapy (P = 0.036).
  • The study's findings laid the foundation for the large-scale standardized clinical application of SDCT in the future and provided an optional novel approach for postoperative risk stratification and chemotherapy beneficiary selection in LARCs.

Statistics:

  • 204 LARC patients were included in the study
  • AUC values of 0.95 and 0.93 were achieved in the training and validation cohorts, respectively
  • 3D spectral CT-based fusion model predicted prognosis and postoperative adjuvant chemotherapy benefit in LARCs
  • Patients in the high-risk group showed a favorable response to postoperative adjuvant chemotherapy (P = 0.036)

Sources:

  • Scientific Reports, 2025,15(1):1-14. (Scientific Reports - http://www.nature.com/srep/index.html)
  • 3D spectral CT-based fusion model predicts prognosis and postoperative adjuvant chemotherapy benefit in locally advanced rectal cancer, doi: 10.1038/s41598-025-14851-x.